Tags

Type your tag names separated by a space and hit enter

Increased serum soluble OX40 in patients with systemic sclerosis.
J Rheumatol. 2008 Dec; 35(12):2359-62.JR

Abstract

OBJECTIVE

To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc).

METHODS

Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals.

RESULTS

OX40 levels were significantly elevated in SSc patients (125.7 +/- 5.7 pg/ml) compared to patients with SLE (80.7 +/- 1.7 pg/ml; p < 0.005) and controls (88.2 +/- 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05).

CONCLUSION

Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

Authors+Show Affiliations

Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18843780

Citation

Komura, Kazuhiro, et al. "Increased Serum Soluble OX40 in Patients With Systemic Sclerosis." The Journal of Rheumatology, vol. 35, no. 12, 2008, pp. 2359-62.
Komura K, Yoshizaki A, Kodera M, et al. Increased serum soluble OX40 in patients with systemic sclerosis. J Rheumatol. 2008;35(12):2359-62.
Komura, K., Yoshizaki, A., Kodera, M., Iwata, Y., Ogawa, F., Shimizu, K., Wayaku, T., Yukami, T., Murata, M., Hasegawa, M., Fujimoto, M., Takehara, K., & Sato, S. (2008). Increased serum soluble OX40 in patients with systemic sclerosis. The Journal of Rheumatology, 35(12), 2359-62.
Komura K, et al. Increased Serum Soluble OX40 in Patients With Systemic Sclerosis. J Rheumatol. 2008;35(12):2359-62. PubMed PMID: 18843780.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased serum soluble OX40 in patients with systemic sclerosis. AU - Komura,Kazuhiro, AU - Yoshizaki,Ayumi, AU - Kodera,Masanari, AU - Iwata,Yohei, AU - Ogawa,Fumihide, AU - Shimizu,Kazuhiro, AU - Wayaku,Takamasa, AU - Yukami,Toru, AU - Murata,Maki, AU - Hasegawa,Minoru, AU - Fujimoto,Manabu, AU - Takehara,Kazuhiko, AU - Sato,Shinichi, Y1 - 2008/10/01/ PY - 2008/10/10/pubmed PY - 2009/3/25/medline PY - 2008/10/10/entrez SP - 2359 EP - 62 JF - The Journal of rheumatology JO - J Rheumatol VL - 35 IS - 12 N2 - OBJECTIVE: To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. RESULTS: OX40 levels were significantly elevated in SSc patients (125.7 +/- 5.7 pg/ml) compared to patients with SLE (80.7 +/- 1.7 pg/ml; p < 0.005) and controls (88.2 +/- 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). CONCLUSION: Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/18843780/Increased_serum_soluble_OX40_in_patients_with_systemic_sclerosis_ DB - PRIME DP - Unbound Medicine ER -